Top

Published in:

01-07-2015 | Novel Treatments for Hypertension (T Unger, Section Editor)

Antihypertensive Combination Treatment: State of the Art

Author: M. Burnier

Published in: Current Hypertension Reports | Issue 7/2015

Abstract

An adequate control of blood pressure is essential to reduce the risk of target organ damages and cardiovascular events in patients with hypertension. Yet, it is well recognized that a substantial proportion of treated patients remain hypertensive despite treatment. Several reasons have been evoked to explain why so many patients are not adequately controlled. Among them, medical inertia, a poor long-term adherence, and the need to prescribe several antihypertensive drugs to reach the target blood pressure have been identified as major limitations to the success of antihypertensive therapy. In this context, the use of single-pill combinations (SPC) containing two or three drugs in one pill has an important role in reducing the impact of some of these issues. Indeed, the use of SPC enables to reduce the pill burden and to improve the treatment efficacy without increasing the incidence of side effects. However, besides their major advantages, SPC have also some limitations such as a possible lack of flexibility or a higher cost. The purpose of this review is to discuss the place of SPC in the actual management of hypertension. The active development of new single-pill combinations in last years can be considered as a significant improvement in the physicians’ capacity to treat hypertension effectively.

Waeber B, Brunner HR. Combination antihypertensive therapy: does it have a role in rational therapy? Am J Hypertens. 1997;10(7 Pt 2):131S–7.PubMedCrossRef

Tocci G, Ferrucci A, Guida P, Avogaro A, Comaschi M, Corsini A, et al. An analysis of the management of cardiovascular risk factors in routine clinical practice in Italy: an overview of the main findings of the EFFECTUS study. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2011;18(1):19–30.CrossRef

Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20(12):1322–32.

Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of copd—role of umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687–95.PubMedCentralPubMedCrossRef

Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in aids care panel. Ann Intern Med. 2012;156(11):817–33. W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.PubMedCentralPubMedCrossRef

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 esh/esc guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). J Hypertens. 2013;31(7):1281–357.PubMedCrossRef

Brunner HR, Menard J, Waeber B, Burnier M, Biollaz J, Nussberger J, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 1990;8(1):3–11. discussion 13–19.PubMedCrossRef

Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.CrossRef

Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (hot) randomised trial. Hot study group. Lancet. 1998;351(9118):1755–62.PubMedCrossRef

10.

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.PubMedCrossRef

11.••

Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882–887 e881. Very interesting paper on the issue of drug adherence in primary and secondary prevention demonstrating the true problems in real life.PubMedCrossRef

12.

Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141–7.PubMedCrossRef

13.

Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–7.PubMedCrossRef

14.

Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens. 2015;29(4):247–53.PubMedCrossRef

15.

Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of veterans affairs cooperative study group on antihypertensive agents. N Engl J Med. 1993;328(13):914–21.PubMedCrossRef

16.•

Bronsert MR, Henderson WG, Valuck R, Hosokawa P, Hammermeister K. Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a distributed ambulatory research in therapeutics network (DARTNet) study. J Am Board Fam Med JABFM. 2013;26(5):529–38. An interesting survey on the efficacy of various therpauetic strategies of hypertension in promary care settings.CrossRef

17.

Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andrejak M, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22(12):2379–86.PubMedCrossRef

18.

Schafer HH, Sudano I, Theus GR, Noll G, Burnier M. Target blood pressure attainment with antihypertensive therapy in swiss primary care. Blood Press. 2012;21(4):211–9.PubMedCrossRef

19.

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300.PubMedCrossRef

20.

Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12(8 Pt 1):797–805.PubMedCrossRef

21.

Burnier M, Vuignier Y, Wuerzner G. State-of-the-art treatment of hypertension: established and new drugs. Eur Heart J. 2014;35(9):557–62.PubMedCrossRef

22.

Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development G. Management of hypertension: summary of nice guidance. BMJ. 2011;343:d4891.PubMedCrossRef

23.

Armstrong C. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014;90(7):503–4.PubMed

24.

Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59(5):926–33.PubMedCentralPubMedCrossRef

25.

Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension. 2000;35(5):1025–30.PubMedCrossRef

26.

Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertension treatment (insight). Lancet. 2000;356(9227):366–72.PubMedCrossRef

27.

Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30(8):1656–64.PubMedCrossRef

28.

MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med. 1996;156(3):278–85.PubMedCrossRef

29.

Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110–7.PubMedCrossRef

30.

Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose–response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104–9.PubMedCrossRef

31.

Patel A, Group AC, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the advance trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40.PubMedCrossRef

32.

Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: premier. Hypertension. 2003;41(5):1063–71.PubMedCrossRef

33.

Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens. 2012;14(5):284–92.CrossRef

34.

Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229 e1221–10.CrossRef

35.

Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310–8.PubMedCrossRef

36.

Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270–80.PubMedCrossRef

37.

de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens. 2009;23(8):503–11.PubMedCrossRef

38.

Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (accomplish): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.PubMedCrossRef

39.

Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.PubMedCrossRef

40.

Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (invest): a randomized controlled trial. JAMA. 2003;290(21):2805–16.PubMedCrossRef

41.

Bakris G, Molitch M, Zhou Q, Sarafidis P, Champion A, Bacher P, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the star-let study. J Cardiometab Syndr. 2008;3(1):18–25.PubMedCrossRef

42.

Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the accomplish randomised controlled trial. Lancet. 2013;381(9866):537–45.PubMedCrossRef

43.

Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005;23(4):883–9.PubMedCrossRef

44.

Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens. 2013;31(2):414–21.PubMedCrossRef

45.

Campbell DJ, McGrady M, Prior DL, Coller JM, Boffa U, Shiel L, et al. Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes. Intern Med J. 2013;43(2):137–43.PubMedCrossRef

46.

Basile J, Neutel J. Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. Ther Adv Cardiovasc Dis. 2010;4(2):119–27.PubMedCrossRef

47.

Lanier G, Sankholkar K, Aronow WS. Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists. Am J Ther. 2014;21(5):419–35.PubMedCrossRef

48.

Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the trinity multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.PubMedCrossRef

49.

Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens. 2012;30(10):2047–55.PubMedCrossRef

50.

Toth K, Investigators P. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the pianist study (perindopril-indapamide plus amlodipine in high risk hypertensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–45.PubMedCrossRef

51.

Weir MR, Hsueh WA, Nesbitt SD, Littlejohn 3rd TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertens. 2011;13(6):404–12.CrossRef

52.•

Taddei S. Fixed-dose combination therapy in hypertension: pros. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2012;19(2):55–7. An intersting debate on the pros and cons of using fixed-dose combinations in the, anagement of hypertension. Assocaited with the paper of ANgeli et al. below.CrossRef

53.•

Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2012;19(2):51–4.CrossRef

54.

Burnier M. Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill. Integr Blood Press Control. 2010;3:57–62.PubMedCentralPubMedCrossRef

55.•

Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–25. A careful review of the different techniques of measuring and analysing adherence data with a description of all the pitfalls and limits of the various available techniques.PubMedCrossRef

56.

Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.PubMedCentralPubMedCrossRef

57.

Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin ii receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens. 2013;15(3):193–200.CrossRef

58.

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9.PubMedCrossRef

59.

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.PubMedCrossRef

60.

Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47(6):1039–48.PubMedCrossRef

61.

Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract. 2011;65(2):127–33.PubMedCrossRef

62.

Tung YC, Lin YS, Wu LS, Chang CJ, Chu PH. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens. 2015;17(1):51–8.CrossRef

63.

Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610–8.PubMedCrossRef

Title: Antihypertensive Combination Treatment: State of the Art
Author: M. Burnier
Publication date: 01-07-2015
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 7/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-015-0562-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?

Endothelin Receptor Antagonists: New Hope for Renal Protection?

From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift

Secondary Hypertension in Pregnancy

Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders

New Hypertension Guidelines: Progression or a Step Backwards in Hypertension?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials